EFNA1 Pathways

Overview of attention for article published in Frontiers in Pharmacology, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,052 followers.

Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways https://t.co/DKYCjfCXU2

Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways https://t.co/TbHRbFw3NA

New Research: Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways https://t.co/DxWLS0Grrq #pharmacology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.